ELSA manages a diversified portfolio of minority investments in seven companies in the life sciences industry. In total, the portfolio contains a number of compounds in varying development stages, all of which target multi-billion-Euro markets in the life science sector. A list of current and past investments can be found below.
Glycotope is a clinical stage biotechnology company applying world-leading glyco-biology expertise to develop highly innovative mAb-based therapeutics in immuno-oncology and oncology.The Company’s Glycobodies target specific glyco-epitopes to generate first-in-class products including naked antibodies and bispecifics. Glycotope’s technology provides a platform for the development of additional clinical and pre-clinical programs with an array of modes of action providing a unique offering in the immuno-oncology and oncology space. Immuno-oncology or cancer immunotherapy is completely different from untargeted chemotherapy or “classical” tumor-targeting cytotoxic antibodies. It targets the problem, that cancer cells utilize clever mechanisms to protect themselves from the immune system by pretending to be a normal cell that must be protected, e.g. by inhibiting immune cells from recognition and attack. Immunomodulatory iOnc drugs, e.g. checkpoint antibodies, T cell engager, immune-cytokines or cell therapies and vaccines aim to re-enable the patients´ immune system to recognize and attack the tumor.
DCprime and Glycotope announce licensing agreement and collaboration (press release 25th March 2019):
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
(press release 30th July 2018):
Glycotope Expands Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies (Press release 18th June 2018):
Daiichi Sankyo has teamed up with Glycotope to develop antibody-drug conjugate (press release 30th Oct 2017):
Glycotope secures one of the largest financing rounds in the European biotech sector (Press release 11th March 2014):
Glycotope sichert 100 Mio. EUR zur Finanzierung neuer Medikamente (Pressemeldung vom 11. März 2014):
Myelo Therapeutics GmbH
Myelo Therapeutics is a pharmaceutical company that develops innovative treatments in areas with high unmet medical needs. Its lead compound, Myelo001, is a small molecule for the treatment of patients with chemotherapy-induced neutropenia and thrombocytopenia.
EMA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome
(Myelo press release 24th July 2019):
FDA Grants Myelo Therapeutics Orphan Drug Designation for Myelo001 as Treatment for Acute Radiation Syndrome (Myelo press release 25th September 2018):
Myelo Therapeutics chosen to participate in Elsevier Incubator Project (Myelo press release 1st December 2016):
Myelo Therapeutics behandelt erste Patientin in Phase II Studie
(Pressemeldung Myelo vom 16. April 2016):
Myelo erhält Genehmigung des BfArM zur klinischen Prüfung
(Pressemeldung der ELSA vom 15. Dezember 2015):
Myelo Therapeutics Receives Approval to Start Phase II of Myelo001 in Chemotherapy-induced Neutropenia and Closes Series B Financing Round
(Myelo press release 15th December 2015):
Start der klinischen Entwicklung in den USA - Myelo Therapeutics schließt weitere Finanzierungsrunde ab
(Pressemeldung der Myelo vom 20. Juni 2017):
Myelo Therapeutics conducts successful Pre-IND meeting and completes new financing round
(Myelo press release 20th June 2017):
OctreoPharm Sciences GmbH
OctreoPharm Sciences is a pharmaceutical development company focused on proprietary radiopharmaceuticals for neuroendocrine tumours. Lead product is therapeutic SOMther®, a somatostatin receptor seeking Y-90 labelled peptide that is developed together with SOMscan®, a Ga-68 based companion diagnostic.
Ipsen has closed acquisition of Octreopharm Sciences GmbH (Pressemeldung vom 30. Juni 2015)
ADELHEID GmbH is the principal holding company for AE Pharma GmbH, a promising company in pharma wholesale. AEP will revolutionize the market by offering significant product discounts to pharmacies through its innovative distribution structures. The team consists of leading industry experts, all of whom have a proven track record.
SurgicEye delivers tumor imaging and navigation solutions, as well as tools and services to provide high quality, customized and affordable patient treatment. With declipse®SPECT, SurgicEye released its first product for navigated radio-guided surgery based on the handheld 3-D freehand SPECT/ultrasound imaging technology.
Viomedo provides first online platform to make clinical development radically more efficient
by connecting and aligning all key stakeholders, making innovative therapies available faster, cheaper and easier. For the first time patients have all the information accessible to consider trial participation alongside other therapeutic options while industry has the possibility to enter the most efficiant recruitment channel to avoid high costs through trial delays.